Cordyceps Sunshine Biotech Holdings (RAJAF) Debt to Equity (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Debt to Equity history runs 6 years deep, the most recent figure standing at -$0.87 for Q4 2025.

• In Q4 2025, Debt to Equity rose 27.07% year-over-year to -$0.87; the TTM figure through Dec 2025 stood at -$0.87 (up 27.07% YoY), while the FY2025 annual figure was -$0.87, up 27.07% from the prior year.
• Debt to Equity was -$0.87 for Q4 2025 at Cordyceps Sunshine Biotech Holdings, up from -$1.19 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of -$0.87 in Q4 2025 to a low of -$7.2 in Q4 2021.
• Historically, Debt to Equity has averaged -$2.54 across 5 years, with a median of -$1.73 in 2024.
• The sharpest annual moves came in 2021 and 2023: Debt to Equity surged 94.57% in 2021, then sank 226.29% in 2023.
• A 5-year view of Debt to Equity shows it stood at -$7.2 in 2021, then soared by 87.91% to -$0.87 in 2022, then tumbled by 226.29% to -$2.84 in 2023, then surged by 57.98% to -$1.19 in 2024, then advanced by 27.07% to -$0.87 in 2025.
• The last three Debt to Equity figures came in at -$0.87 (Q4 2025), -$1.19 (Q4 2024), and -$2.84 (Q4 2023), per Business Quant data.